Table 1.
Demographic characteristics of patients with CHC in Taiwan, 2001–2013
| Variables | Total N = 13,203 | CHC treated by PEG IFN/RB N = 3810 | CHC nontreated N = 9393 | P-value |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Age (years) | 0.69 | |||
| < 20 | 612 (4.6) | 183 (4.8) | 429 (4.6) | |
| 21–30 | 2104 (15.9) | 610 (16.0) | 1494 (15.9) | |
| 31–40 | 2607 (19.7) | 723 (19.0) | 1884 (20.1) | |
| 41–50 | 2430 (18.4) | 704 (18.5) | 1726 (18.4) | |
| > 51 | 5450 (41.3) | 1590 (41.7) | 3860 (41.1) | |
| Sex | 0.84 | |||
| Female | 6733 (51.0) | 1980 (52.0) | 4753 (50.6) | |
| Male | 6470 (49.0) | 1830 (48.0) | 4640 (49.4) | |
| Region of residence | 0.03 | |||
| Northern | 3549 (26.9) | 948 (24.9) | 2601 (27.7) | |
| Central | 3772 (28.6) | 1149 (30.2) | 2623 (27.9) | |
| Southern | 5019 (38.0) | 1450 (38.1) | 3569 (38) | |
| Eastern | 863 (6.5) | 263 (6.9) | 600 (6.4) | |
| Diagnosed with TD | < 0.001 | |||
| Yes | 417 (3.2) | 173 (4.5) | 244 (2.6) | |
| No | 12,786 (96.8) | 3637 (95.5) | 9149 (97.4) | |
| Past history | ||||
| Hypertension | < 0.001 | |||
| Yes | 6908 (52.3) | 1759 (46.2) | 5149 (54.8) | |
| No | 6295 (47.7) | 2051 (53.8) | 4244 (45.2) | |
| Hyperlipidemia | 0.901 | |||
| Yes | 4642 (35.2) | 1383 (36.3) | 3259 (34.7) | |
| No | 8561 (64.8) | 2427 (63.7) | 6134 (65.3) | |
| Diabetes mellitus | < 0.001 | |||
| Yes | 4282 (32.4) | 1164 (30.6) | 3118 (33.2) | |
| No | 8921 (67.6) | 2646 (69.4) | 6275 (66.8) | |
| Liver cirrhosis | 0.003 | |||
| Yes | 2916 (22.1) | 756 (19.8) | 2160 (23.0) | |
| No | 10,287 (77.9) | 3054 (80.2) | 7233 (77.0) | |
| CKD | < 0.001 | |||
| Yes | 2473 (18.7) | 552 (14.5) | 1921 (20.5) | |
| No | 10,730 (81.3) | 3258 (85.5) | 7472 (79.5) | |
| Goiter | 0.48 | |||
| Yes | 485 (3.7) | 133 (3.5) | 352 (3.7) | |
| No | 12,718 (96.3) | 3677 (96.5) | 9041 (96.3) | |
CHC chronic hepatitis C, TD thyroid dysfunction, CKD chronic kidney disease, PEG-IFN/RBV pegylated interferon/ribavirin